A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Blonanserin (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 27 Sep 2013 Based on positive results in this trial, an application for registration of blonanserin for the treatment of schizophrenia has been submitted in China, according to a Dainippon Sumitomo Pharma media release.
- 14 Nov 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
- 14 Nov 2012 Planned End Date changed from 1 Nov 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov record.